Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Arrowhead Pharma
(NQ:
ARWR
)
19.62
+0.20 (+1.03%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arrowhead Pharma
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Where Arrowhead Pharmaceuticals Stands With Analysts
May 24, 2022
Within the last quarter, Arrowhead Pharmaceuticals (NASDAQ:ARWR) has observed the following analyst ratings:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2022
May 11, 2022
Upgrades
Via
Benzinga
Arrowhead Pharmaceuticals: Q2 Earnings Insights
May 10, 2022
Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported its Q2 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Arrowhead Pharmaceuticals Reports Fiscal 2022 Second Quarter Results
May 10, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
May 10, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Arrowhead Breaks Ground on New Manufacturing Facility with Wisconsin Governor Tony Evers and Announces Receipt of Incentives
May 09, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Appoints Victoria Vakiener to Board of Directors
May 02, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming May 2022 Conferences
May 02, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Week In Review: I-Mab Files For Hong Kong SPAC IPO To Acquire Life Science Company
April 30, 2022
I-Mab and one of its investors, VMS, have filed for a Hong Kong IPO of a SPAC that will raise funds to acquire a life science company. Also, RVAC Medicines completed a Series B funding that brings...
Via
Talk Markets
Arrowhead Pharmaceuticals to Host Pulmonary R&D Day
April 27, 2022
From
Arrowhead Pharmaceuticals Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Initiates Phase 2 GATEWAY Study of Investigational ARO-ANG3 for Treatment of Homozygous Familial Hypercholesterolemia
April 26, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals and Vivo Capital Launch Joint Venture Aimed at Greater China Market
April 25, 2022
From
Arrowhead Pharmaceuticals Inc.
Via
Business Wire
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
April 24, 2022
Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering...
Via
Benzinga
Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Second Quarter Results
April 20, 2022
From
Arrowhead Pharmaceuticals Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
April 06, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming April 2022 Conferences
April 01, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MUC5AC for Treatment of Muco-Obstructive Lung Diseases
March 24, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-RAGE for Treatment of Asthma
March 15, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Completes Enrollment in Phase 2b ARCHES-2 Study of Investigational ARO-ANG3 for Patients with Mixed Dyslipidemia
February 24, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
February 23, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Arrowhead Pharmaceuticals, Inc. (ARWR) Investigation
February 21, 2022
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Arrowhead Pharmaceuticals, Inc. (ARWR) Investigation
February 18, 2022
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases
February 18, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Presents New Clinical Data on ARO-HIF2 at ASCO GU 2022
February 17, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
The Best Russell 2000 Stocks to Buy Before they Rebound
February 15, 2022
Some of the best stocks in the market are among the best Russell 2000 stocks to buy. Here's a list of a few of those choices.
Via
InvestorPlace
Arrowhead Pharmaceuticals's Return On Capital Employed Insights
February 03, 2022
According to data from Benzinga Pro, during Q1, Arrowhead Pharmaceuticals's (NASDAQ:ARWR) reported sales totaled $27.44 million. Despite a 0.79% increase in earnings, the company posted a loss of...
Via
Benzinga
The Daily Biotech Pulse: Big Pharma Earnings Prove Lackluster, Mersana Inks $1B ADC R&D Deal, Syros Gets Orphan Drug Designation
February 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Recap: Arrowhead Pharmaceuticals Q1 Earnings
February 03, 2022
Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported its Q1 earnings results on Wednesday, February 2, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Arrowhead Pharmaceuticals Reports Fiscal 2022 First Quarter Results
February 02, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
The Daily Biotech Pulse: LogicBio Genome Editing Therapy Study Placed On Clinical Hold, Gilead Q4 Disappoints On Slowing Veklury Sales
February 02, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.